Opendata, web and dolomites

TrojanDC SIGNED

TrojanDC

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TrojanDC project word cloud

Explore the words cloud of the TrojanDC project. It provides you a very rough idea of what is the project "TrojanDC" about.

locked    cells    data    tumoral    demand    grant    dendritic    patients    consistently    urgent    company    therapeutics    tumor    shifting    something    diversity    start    swedish    price    lose    technologies    maximizing    eradicate    antigen    reprogramming    educates    proprietary    fastest    scientists    robustly    merck    anti    14    paradigm    form    transcription    markets    approx    named    immunotherapy    sme    acquisitions    trojandc    costing    team    roche    cell    limited    size    commercialization       fits    despite    oncology    asgard    chances    antigens    heterogeneous    effectiveness    entrepreneurs    inducing    vector    injection    keen    seasoned    health    uses    cancer    combination    sound    therapy    balanced    resistance    presenting    overhaul    players    bms    shown    shortcomings    global    founded    cagr    viral    strategy    instrument    efficacy    immune    market    genes    2024    re    personalized    immunotherapies    immunogenic    performing    delivers    114    proof    gene    effector    innovative    critical    develops    car    vivo    reliably    patient    350k   

Project "TrojanDC" data sheet

The following table provides information about the project.

Coordinator
ASGARD THERAPEUTICS AB 

Organization address
address: REVINGEGATAN 19C 1203
city: LUND
postcode: 223 59
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASGARD THERAPEUTICS AB SE (LUND) coordinator 50˙000.00

Map

 Project objective

Asgard Therapeutics, a Swedish start-up company, was founded based on a unique proprietary in vivo cell reprogramming technology. This paradigm-shifting gene therapy has the unique potential to overhaul the cancer immunotherapy market.

Our gene therapy, named TrojanDC, delivers immune-genes into the tumor and re-educates cancer cells to become anti-tumor immune cells. It uses a viral vector to deliver a unique combination of three critical transcription factors (genes) through intra-tumoral injection. The transcription factors make cancer cells become antigen-presenting dendritic cells. These immunogenic cells present their own diversity of tumor-specific antigens to effector immune cells, reliably and robustly inducing immune responses that eradicate the heterogeneous tumor.

Cancer remains a major health challenge. Currently available immunotherapies show strong effectiveness only in a limited number of patients, and often lose their efficacy as the tumor develops resistance. In addition, immunotherapies come with high price (e.g. CAR-T cell approach costing approx. € 350k/patient). Despite these shortcomings, the global immune-oncology market is one of the fastest growing therapeutics markets (€114.6 B by 2024 with a CAGR of 14.3%). Large players like BMS, Merck and Roche have shown to be keen on acquisitions of high-potential technologies. There is thus an urgent need and high demand for innovative cost-effective immunotherapies consistently effective in a broader range of cancer patients – something that Asgard Therapeutics will deliver with TrojanDC in the form of a personalized and highly specific immune therapy using a ‘one-size-fits-all’ approach.

With in-vivo proof-of-concept data already obtained and a balanced team of high-performing scientists and seasoned entrepreneurs, Asgard Therapeutics has locked up key factors towards maximizing its chances of success. This SME instrument grant will ensure a sound strategy towards commercialization of TrojanDC.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TROJANDC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TROJANDC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More  

Path Feel (2019)

Insoles for Neuropathy and Balance Issues

Read More